Globus Medical, Inc. $GMED Shares Sold by Vestcor Inc

Posted by Francis Steltz on Jun 11th, 2026

Vestcor Inc reduced its position in Globus Medical, Inc. (NYSE:GMED – Free Report) by 88.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 941 shares of the medical device company’s stock after selling 7,196 shares during the quarter. Vestcor Inc’s holdings in Globus Medical were worth $82,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in GMED. SBI Securities Co. Ltd. lifted its stake in shares of Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after buying an additional 167 shares in the last quarter. Advisory Services Network LLC purchased a new position in shares of Globus Medical in the third quarter worth about $26,000. EverSource Wealth Advisors LLC lifted its stake in shares of Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after buying an additional 197 shares in the last quarter. Larson Financial Group LLC lifted its stake in shares of Globus Medical by 83.4% in the fourth quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock worth $46,000 after buying an additional 242 shares in the last quarter. Finally, Parallel Advisors LLC lifted its stake in shares of Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after buying an additional 173 shares in the last quarter. 95.16% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

GMED has been the topic of several research reports. Wall Street Zen downgraded shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Royal Bank Of Canada upped their target price on Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Wells Fargo & Company dropped their target price on Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Finally, Truist Financial set a $115.00 target price on Globus Medical in a report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $106.36.

Check Out Our Latest Stock Analysis on GMED

Globus Medical Trading Down 1.8%

NYSE GMED opened at $81.02 on Thursday. The stock has a market cap of $11.00 billion, a PE ratio of 18.84, a P/E/G ratio of 1.70 and a beta of 0.95. Globus Medical, Inc. has a twelve month low of $51.79 and a twelve month high of $101.40. The stock has a fifty day simple moving average of $86.03 and a 200-day simple moving average of $88.19.

Globus Medical (NYSE:GMED – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The business had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The company’s revenue was up 27.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Research analysts predict that Globus Medical, Inc. will post 4.74 EPS for the current year.

Insider Buying and Selling at Globus Medical

In other news, Director David D. Davidar sold 25,000 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the transaction, the director directly owned 510,175 shares in the company, valued at approximately $41,201,733. This represents a 4.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 18.38% of the company’s stock.

About Globus Medical

(Free Report)

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.